APA (7th ed.) Citation

DM, W., T, G., M, H., RM, S., GJ, S., L, L., . . . S, J. (2012). Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clinical lymphoma, myeloma & leukemia, 12(5), 319. https://doi.org/10.1016/j.clml.2012.07.007

Chicago Style (17th ed.) Citation

DM, Weber, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, and Jagannath S. "Phase I Trial of Vorinostat Combined with Bortezomib for the Treatment of Relapsing And/or Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia 12, no. 5 (2012): 319. https://doi.org/10.1016/j.clml.2012.07.007.

MLA (9th ed.) Citation

DM, Weber, et al. "Phase I Trial of Vorinostat Combined with Bortezomib for the Treatment of Relapsing And/or Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia, vol. 12, no. 5, 2012, p. 319, https://doi.org/10.1016/j.clml.2012.07.007.